These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 19777391)

  • 1. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.
    Hendrickson AW; Haluska P
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1032-40. PubMed ID: 19777391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy.
    Bähr C; Groner B
    Growth Horm IGF Res; 2004 Aug; 14(4):287-95. PubMed ID: 15231297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The insulin-like growth factor 1 receptor in cancer: old focus, new future.
    Hartog H; Wesseling J; Boezen HM; van der Graaf WT
    Eur J Cancer; 2007 Sep; 43(13):1895-904. PubMed ID: 17624760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.
    Mitsiades CS; Mitsiades N
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):487-99. PubMed ID: 16001956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer.
    Tao Y; Pinzi V; Bourhis J; Deutsch E
    Nat Clin Pract Oncol; 2007 Oct; 4(10):591-602. PubMed ID: 17898809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F; Lee HY
    Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer.
    Ryan PD; Goss PE
    Oncologist; 2008 Jan; 13(1):16-24. PubMed ID: 18245009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting insulin-like growth factor 1 receptor in sarcomas.
    Scotlandi K; Picci P
    Curr Opin Oncol; 2008 Jul; 20(4):419-27. PubMed ID: 18525338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.
    Garofalo C; Manara MC; Nicoletti G; Marino MT; Lollini PL; Astolfi A; Pandini G; López-Guerrero JA; Schaefer KL; Belfiore A; Picci P; Scotlandi K
    Oncogene; 2011 Jun; 30(24):2730-40. PubMed ID: 21278796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
    Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras.
    Chinnaiyan P; Allen GW; Harari PM
    Semin Radiat Oncol; 2006 Jan; 16(1):59-64. PubMed ID: 16378908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor-I receptor signaling blockade combined with radiation.
    Allen GW; Saba C; Armstrong EA; Huang SM; Benavente S; Ludwig DL; Hicklin DJ; Harari PM
    Cancer Res; 2007 Feb; 67(3):1155-62. PubMed ID: 17283150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF1R signalling and its inhibition.
    Riedemann J; Macaulay VM
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S33-43. PubMed ID: 17259557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
    Jernberg-Wiklund H; Nilsson K
    Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
    Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy.
    Adachi Y; Lee CT; Carbone DP
    Novartis Found Symp; 2004; 262():177-89; discussion 190-2, 265-8. PubMed ID: 15562829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor.
    Surmacz E
    Oncogene; 2003 Sep; 22(42):6589-97. PubMed ID: 14528284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The IGF receptor as anticancer treatment target.
    Macaulay VM
    Novartis Found Symp; 2004; 262():235-43; discussion 243-6, 265-8. PubMed ID: 15562833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.